Literature DB >> 28913473

The impact of donor liver graft quality on postoperative outcome in liver transplant recipients. A single centre experience.

Dana Tomescu1,2, Mihai Popescu2, Lavinia Jipa3, Ruxandra Fota3, Daniela Ungureanu3, Radu Zamfir4, Carmen Orban1, Simona Olimpia Dima4, Irinel Popescu4.   

Abstract

INTRODUCTION: The Donor Risk Index (DRI) has become a universal score for organ allocation in liver transplantation (LT) worldwide. The aim of this study was to evaluate the impact of liver graft quality measured by DRI, CIT, WIT and donor age on intraoperative hemodynamics (reperfusion syndrome) and early postoperative outcome, defined as initial graft poor function (within 3 days of LT), of deceased donor liver transplant (DDLT) recipients. Secondary end-points were the assessment of the impact of graft quality on the intraoperative and postoperative day 1 hemostasis (evaluated using ROTEM assay).
METHODS: We retrospectively analyzed 135 patients who underwent deceased-donor LT between January 2013 and December 2014. Patient demographic data (age, sex, cause of End-Stage Liver Disease), preoperative paraclinical data (total bilirubin, creatinine, serum sodium), severity of liver disease scores (Model for End-Stage Liver Disease - MELD and MELD-sodium), intraoperative blood loss and blood products transfusion, incidence of post reperfusion syndrome, postoperative biochemical data (including total bilirubin, hepatic transaminases, lactate levels) and outcome (initial graft poor function diagnosis) were noted. Donor characteristics including DRI, CIT, WIT and donor age were noted. Coagulation was assessed by rotational thromboelastometry (ROTEM) after reperfusion of the graft and on postoperative day 1 in order to determine the effects of liver graft quality on hemostasis.
RESULTS: Donor age has significantly correlated with decreased derived ROTEM parameters time to the maximum velocity of clot formation - MaxVt (p = 0.000), area under the curve (AUC) (p = 0.008) and maximum clot elasticity (MCE) (p = 0.018) although no difference in transfusion requirements has been observed. A longer CIT was associated with an increase in AST and ALT observed during the early postoperative period: day 1 ALT (p = 0.032) and AST (p = 0.008), day 2 ALT (p = 0.001) and AST (p = 0.001) and day 3 AST (p = 0.010) and ALT (p = 0.001). Higher DRI correlated with higher bilirubin levels measured on postoperative day 1 (p = 0.027) and 2 (p = 0.001). Patients who developed initial graft poor function received liver grafts from older donors (p = 0.05) with a higher DRI (p = 0.002).
CONCLUSION: Our results suggest a significant impact of donor age and DRI on perioperative coagulation kinetics that may be a result of initial graft poor function. Although CIT and DRI correlated with a more severe cholestasis and hepatocitolysis during the early postoperative period these seems to be short-lived.

Entities:  

Keywords:  cirrhotic coagulopathy; liver graft; liver transplantation; outcome

Year:  2016        PMID: 28913473      PMCID: PMC5505359          DOI: 10.21454/rjaic.7518.231.gft

Source DB:  PubMed          Journal:  Rom J Anaesth Intensive Care        ISSN: 2392-7518


  13 in total

1.  Donor Age-Based Analysis of Liver Transplantation Outcomes: Short- and Long-Term Outcomes Are Similar Regardless of Donor Age.

Authors:  William C Chapman; Neeta Vachharajani; Kelly M Collins; Jackie Garonzik-Wang; Yikyung Park; Jason R Wellen; Yiing Lin; Surendra Shenoy; Jeffrey A Lowell; M B Majella Doyle
Journal:  J Am Coll Surg       Date:  2015-02-28       Impact factor: 6.113

2.  Declining liver graft quality threatens the future of liver transplantation in the United States.

Authors:  Eric S Orman; Maria E Mayorga; Stephanie B Wheeler; Rachel M Townsley; Hector H Toro-Diaz; Paul H Hayashi; A Sidney Barritt
Journal:  Liver Transpl       Date:  2015-08       Impact factor: 5.799

3.  The Eurotransplant donor risk index in liver transplantation: ET-DRI.

Authors:  A E Braat; J J Blok; H Putter; R Adam; A K Burroughs; A O Rahmel; R J Porte; X Rogiers; J Ringers
Journal:  Am J Transplant       Date:  2012-07-23       Impact factor: 8.086

4.  Donor factors similarly impact survival outcome after liver transplantation in hepatocellular carcinoma and non-hepatocellular carcinoma patients.

Authors:  Reena J Salgia; Nathan P Goodrich; Jorge A Marrero; Michael L Volk
Journal:  Dig Dis Sci       Date:  2014-01       Impact factor: 3.199

5.  The Donor-Risk-Index, ECD-Score and D-MELD-Score all fail to predict short-term outcome after liver transplantation with acceptable sensitivity and specificity.

Authors:  Harald Schrem; Benedikt Reichert; Nils Frühauf; Thomas Becker; Frank Lehner; Moritz Kleine; Hüseyin Bektas; Lea Zachau; Jürgen Klempnauer
Journal:  Ann Transplant       Date:  2012 Jul-Sep       Impact factor: 1.530

Review 6.  Donor Hepatic Steatosis and Outcome After Liver Transplantation: a Systematic Review.

Authors:  Michael J J Chu; Anna J Dare; Anthony R J Phillips; Adam S J R Bartlett
Journal:  J Gastrointest Surg       Date:  2015-04-28       Impact factor: 3.452

7.  Potential predictive value of the MELD score for short-term mortality after liver transplantation.

Authors:  G Santori; E Andorno; A Antonucci; N Morelli; G Bottino; R Mondello; R Valente; F Panaro; F Ravazzoni; S Di Domenico; A Savelli; U Valente
Journal:  Transplant Proc       Date:  2004-04       Impact factor: 1.066

8.  The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors.

Authors:  E Mor; G B Klintmalm; T A Gonwa; H Solomon; M J Holman; J F Gibbs; I Watemberg; R M Goldstein; B S Husberg
Journal:  Transplantation       Date:  1992-02       Impact factor: 4.939

Review 9.  The utility of marginal donors in liver transplantation.

Authors:  Ronald W Busuttil; Koichi Tanaka
Journal:  Liver Transpl       Date:  2003-07       Impact factor: 5.799

10.  Use of severely steatotic grafts in liver transplantation: a matched case-control study.

Authors:  Lucas McCormack; Henrik Petrowsky; Wolfram Jochum; Beat Mullhaupt; Markus Weber; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.